Aurinia Pharmaceuticals' (AUPH) "Hold (C)" Rating Reaffirmed at Weiss Ratings

Key Points

• Aurinia Pharmaceuticals' stock maintains a "hold (C)" rating from Weiss Ratings, amidst differing opinions from other analysts, with two ratings at "buy" and one at "hold."
• The company's shares are currently trading at $11.53, with a year high of $13.54 and a market cap of $1.52 billion.
• Significant insider buying was reported, including Director Kevin Tang's purchase of 1,000,000 shares, increasing his ownership to nearly 11 million shares.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP's stock had its "hold (c)" rating reiterated by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other research firms also recently commented on AUPH. HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Royal Bank Of Canada raised their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock traded down $0.18 during mid-day trading on Wednesday, reaching $11.53. The stock had a trading volume of 1,132,316 shares, compared to its average volume of 1,656,888. The firm's 50 day simple moving average is $11.94 and its 200 day simple moving average is $9.46. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals has a one year low of $6.55 and a one year high of $13.54. The firm has a market cap of $1.52 billion, a PE ratio of 26.81 and a beta of 1.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Aurinia Pharmaceuticals will post 0.11 EPS for the current year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Kevin Tang acquired 1,000,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, August 1st. The stock was bought at an average cost of $10.12 per share, with a total value of $10,120,000.00. Following the completion of the transaction, the director directly owned 11,029,500 shares of the company's stock, valued at approximately $111,618,540. This represents a 9.97% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 1,300,000 shares of company stock worth $13,590,000 over the last ninety days. 12.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Union Bancaire Privee UBP SA acquired a new position in Aurinia Pharmaceuticals during the third quarter valued at approximately $136,000. City Center Advisors LLC boosted its position in Aurinia Pharmaceuticals by 24.1% during the third quarter. City Center Advisors LLC now owns 32,452 shares of the biotechnology company's stock valued at $359,000 after purchasing an additional 6,297 shares during the last quarter. Corient Private Wealth LLC boosted its position in Aurinia Pharmaceuticals by 57.3% during the second quarter. Corient Private Wealth LLC now owns 29,560 shares of the biotechnology company's stock valued at $250,000 after purchasing an additional 10,768 shares during the last quarter. Osaic Holdings Inc. boosted its position in Aurinia Pharmaceuticals by 43.9% during the second quarter. Osaic Holdings Inc. now owns 34,677 shares of the biotechnology company's stock valued at $294,000 after purchasing an additional 10,585 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its position in Aurinia Pharmaceuticals by 195.4% during the second quarter. Squarepoint Ops LLC now owns 483,937 shares of the biotechnology company's stock valued at $4,099,000 after purchasing an additional 320,124 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.